Gonçalves Filipe Marques, Neis Vivian Binder, Rieger Débora Kurrle, Lopes Mark William, Heinrich Isabella A, Costa Ana Paula, Rodrigues Ana Lúcia S, Kaster Manuella P, Leal Rodrigo Bainy
Biochemistry Graduate Program, Center of Biological Sciences, Universidade Federal de Santa Catarina, Florianópolis, SC, Brazil.
Department of Nutrition, Center of Health Science, Universidade Federal de Santa Catarina, Florianópolis, SC, Brazil.
Purinergic Signal. 2017 Jun;13(2):203-214. doi: 10.1007/s11302-016-9551-2. Epub 2016 Dec 13.
Inosine is a purine nucleoside formed by the breakdown of adenosine that elicits an antidepressant-like effect in mice through activation of adenosine A and A receptors. However, the signaling pathways underlying this effect are largely unknown. To address this issue, the present study investigated the influence of extracellular-regulated protein kinase (ERK)1/2, Ca/calmoduline-dependent protein kinase (CaMKII), protein kinase A (PKA), phosphoinositide 3-kinase (PI3K)/Akt, and glycogen synthase kinase 3beta (GSK-3β) modulation in the antiimmobility effect of inosine in the tail suspension test (TST) in mice. In addition, we attempted to verify if inosine treatment was capable of altering the immunocontent and phosphorylation of the transcription factor cyclic adenosine monophosphatate (cAMP) response-binding element protein (CREB) in mouse prefrontal cortex and hippocampus. Intracerebroventricular administration of U0126 (5 μg/mouse, MEK1/2 inhibitor), KN-62 (1 μg/mouse, CaMKII inhibitor), H-89 (1 μg/mouse, PKA inhibitor), and wortmannin (0.1 μg/mouse, PI3K inhibitor) prevented the antiimmobility effect of inosine (10 mg/kg, intraperitoneal (i.p.)) in the TST. Also, administration of a sub-effective dose of inosine (0.1 mg/kg, i.p.) in combination with a sub-effective dose of AR-A014418 (0.001 μg/mouse, GSK-3β inhibitor) induced a synergic antidepressant-like effect. None of the treatments altered locomotor activity of mice. Moreover, 24 h after a single administration of inosine (10 mg/kg, i.p.), CREB phosphorylation was increased in the hippocampus. Our findings provided new evidence that the antidepressant-like effect of inosine in the TST involves the activation of PKA, PI3K/Akt, ERK1/2, and CaMKII and the inhibition of GSK-3β. These results contribute to the comprehension of the mechanisms underlying the purinergic system modulation and indicate the intracellular signaling pathways involved in the antidepressant-like effect of inosine in a preclinical test of depression.
肌苷是一种由腺苷分解形成的嘌呤核苷,它通过激活腺苷A1和A2受体在小鼠中引发抗抑郁样效应。然而,这种效应背后的信号通路在很大程度上尚不清楚。为了解决这个问题,本研究调查了细胞外调节蛋白激酶(ERK)1/2、钙/钙调蛋白依赖性蛋白激酶(CaMKII)、蛋白激酶A(PKA)、磷酸肌醇3激酶(PI3K)/Akt和糖原合酶激酶3β(GSK-3β)的调节对肌苷在小鼠悬尾试验(TST)中的抗不动效应的影响。此外,我们试图验证肌苷治疗是否能够改变小鼠前额叶皮质和海马中转录因子环磷酸腺苷(cAMP)反应结合元件蛋白(CREB)的免疫含量和磷酸化。脑室内注射U0126(5μg/小鼠,MEK1/2抑制剂)、KN-62(1μg/小鼠,CaMKII抑制剂)、H-89(1μg/小鼠,PKA抑制剂)和渥曼青霉素(0.1μg/小鼠,PI-3K抑制剂)可预防肌苷(10mg/kg,腹腔注射(i.p.))在TST中的抗不动效应。此外,给予次有效剂量的肌苷(0.1mg/kg,i.p.)与次有效剂量的AR-A014418(0.001μg/小鼠,GSK-3β抑制剂)联合使用可诱导协同抗抑郁样效应。所有处理均未改变小鼠的运动活性。此外,单次腹腔注射肌苷(10mg/kg)24小时后,海马中CREB磷酸化增加。我们的研究结果提供了新的证据,表明肌苷在TST中的抗抑郁样效应涉及PKA、PI3K/Akt、ERK1/2和CaMKII的激活以及GSK-3β的抑制。这些结果有助于理解嘌呤能系统调节的潜在机制,并指出在抑郁症临床前试验中肌苷抗抑郁样效应所涉及的细胞内信号通路。